US Patent

US8815301 — Stable iron oligosaccharide compound

Method of Use · Assigned to Pharmacosmos Holding AS · Expires 2029-08-14 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable iron oligosaccharide compound used to treat iron deficiency anemia.

USPTO Abstract

The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2734 — Monoferric
U-2734 — Monoferric
U-2734 — Monoferric

Patent Metadata

Patent number
US8815301
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pharmacosmos Holding AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.